Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report)'s stock price was down 7.3% during trading on Thursday . The company traded as low as $8.33 and last traded at $8.2220. 105,578 shares changed hands during trading, a decline of 89% from the average daily volume of 925,923 shares. The stock had previously closed at $8.87.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Wednesday, June 24th. Wall Street Zen lowered Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. JPMorgan Chase & Co. cut their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kyverna Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.
Read Our Latest Stock Report on KYTX
Kyverna Therapeutics Trading Down 7.8%
The firm has a market cap of $505.85 million, a price-to-earnings ratio of -2.78 and a beta of 1.93. The company's 50-day moving average price is $8.14 and its 200-day moving average price is $8.43. The company has a quick ratio of 9.06, a current ratio of 9.06 and a debt-to-equity ratio of 0.15.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.05. Equities analysts expect that Kyverna Therapeutics, Inc. will post -2.7 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Kyverna Therapeutics during the 2nd quarter valued at about $27,931,000. AIGH Capital Management LLC acquired a new position in shares of Kyverna Therapeutics during the 2nd quarter worth approximately $24,911,000. Price T Rowe Associates Inc. MD grew its position in shares of Kyverna Therapeutics by 16.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company's stock valued at $16,569,000 after purchasing an additional 250,418 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $15,667,000. Finally, Vanguard Group Inc. increased its holdings in shares of Kyverna Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company's stock valued at $7,936,000 after purchasing an additional 9,858 shares during the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
